Related Experiment Videos
Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children
P E Palumbo1, C Raskino, S Fiscus
1Department of Pediatrics, University of Medicine and Dentistry of New Jersey, Newark 07103, USA. ppalumbo@daiid.umdnj.edu
Insights
Plasma RNA and CD4+ counts predict pediatric HIV progression. Lowering viral load is key for better outcomes in children with HIV infection, with specific targets for optimal results.
Area of Science:
- Pediatric Infectious Diseases
- Virology
- Immunology
Background:
- Pediatric human immunodeficiency virus (HIV) infection presents unique pathogenetic features distinct from adult cases.
- Extrapolation of adult study findings to children is not routinely feasible, necessitating specific pediatric analyses.
Purpose of the Study:
- To assess the prognostic significance of plasma RNA and CD4+ lymphocyte counts in pediatric HIV disease progression.
- To establish target values for these markers to achieve optimal clinical outcomes in children.
Main Methods:
- Analysis of data from 566 antiretroviral therapy-naive children in the ACTG 152 trial (1991-1995).
- Median follow-up of 32 months with clinical endpoints including disease progression (growth failure, neurological decline, opportunistic infections) or death.
Main Results:
- Baseline plasma RNA and CD4+ counts were independent predictors of clinical course.
- Each log10 reduction in baseline RNA correlated with a 49%-64% risk reduction for disease progression.
- Combined use of plasma RNA and CD4+ counts enhanced predictive power for disease progression.
Conclusions:
- Plasma RNA and CD4+ lymphocyte counts are crucial independent predictors of clinical outcomes in pediatric HIV.
- The linear, age-independent relationship between log10 plasma RNA and disease progression risk supports aggressive viral load reduction therapies.
Context:
Pediatric human immunodeficiency virus (HIV) infection has unique viral pathogenetic features that preclude routine extrapolation from adult studies and require specific analysis.
Objectives:
To evaluate the prognostic value of 2 key laboratory markers-plasma RNA and CD4+ lymphocyte count-for HIV disease progression in infants and children and to establish targeted values for optimal outcome.
Design:
Data from a cohort of 566 infants and children who participated in a randomized, placebo-controlled trial of nucleoside reverse transcriptase inhibitors (ACTG 152) were analyzed. The trial was conducted between 1991 and 1995 and enrolled a heterogeneous cohort of antiretroviral therapy-naive children (age, 3 months to 18 years); patients had a median follow-up of 32 months.
Main Outcome Measures:
The trial clinical end points consisted of time to first HIV disease progression (growth failure, decline in neurologic or neurodevelopmental function, opportunistic infections) or death.
Results:
Baseline plasma RNA levels were high (age group medians, 5 x 10(4) to >10(6) copies/mL), and both baseline RNA and CD4+ lymphocyte count were independently predictive of subsequent clinical course. Risk reduction for disease progression between 49% and 64% was observed for each log10 reduction in baseline RNA and was linear without suggestion of a threshold or age effect. Disease progression predictive power was enhanced by the combined use of plasma RNA and CD4+ cell count. Marker values of less than 10000 copies/mL for plasma RNA and greater than 500 x 10(6)/L (<6.5 years of age) or greater than 200 x 10(6)/L (>6.5 years) for CD4+ cell count were associated with a 2-year disease progression rate of less than 5%.
Conclusions:
Two key laboratory markers--plasma RNA and CD4+ lymphocyte count-are independent predictors of clinical course among HIV-infected infants and children. The linear, age-independent relationship between log10 plasma RNA and relative risk of disease progression strongly supports therapeutic efforts to achieve plasma virus levels as low as possible.